Navigation Links
Venaxis to Present at Piper Jaffray 25th Annual Healthcare Conference
Date:11/21/2013

is.  This unique appendicitis test has projected high sensitivity and negative predictive value and is being developed to aid in the identification of patients at low risk for acute appendicitis, allowing for more conservative patient management.  The APPY1 Test is being developed initially for pediatric, adolescent and young adult patients with abdominal pain, as this population is at the highest risk for appendicitis and has the highest risk of long-term health effects associated with CT imaging.  While FDA clearance is being sought, an initial launch for the APPY1 Test is ongoing in select European countries.  For more information, visit www.venaxis.com.

Forward-Looking Statements
This press release includes "forward-looking statements" of Venaxis, Inc. ("Venaxis") as defined by the Securities and Exchange Commission ("SEC"). All statements, other than statements of historical fact, included in this press release that address activities, events or developments that Venaxis believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors Venaxis believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Venaxis. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including our ability to successfully complete required product development and modifications in a timely and cost effective manner, complete clinical trial activities for the APPY1 Test required for FDA submission, obtain FDA clearance or approval, maintain CE Marking, cost effectively m
'/>"/>

SOURCE Venaxis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Venaxis APPY1 Test Passes Futility Analysis in Pivotal Clinical Study
2. Venaxis Announces Pricing of Offering of Common Stock and Warrants
3. Venaxis Executes First Commercial Development Agreement and Receives Purchase Order from EMELCA Bioscience for Initial EU Launch
4. Dyadic International To Present At Two Major Conferences In December 2013
5. Sangamo BioSciences Announces Seven Data Presentations At The 2013 American Society of Hematology Annual Meeting
6. Aratana Therapeutics to Present at Two Upcoming Investor Conferences
7. Celladon Corporation Announces Oral Presentation at American Heart Association of Long Term Follow-Up Results from the MYDICAR CUPID 1 Trial in Advanced Heart Failure
8. Amgen Presents Interim Overall Survival Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
9. Accuray to Present at Piper Jaffray 25th Annual Healthcare Conference
10. Cartes 2013: DERMALOG Presents World Firsts in Biometrics
11. Proove Biosciences to Present Research on the Genetics of Pain Medicine and Exhibit at ASRA’s 12th Annual Pain Medicine Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... N.C. , Dec. 22, 2014  Alternative ... announced that it has signed a letter of ... that has developed and patented a nanotechnology-based development ... diagnostics products that enable rapid on-site collection and ... use/abuse and health issues in an immediate, non-invasive ...
(Date:12/22/2014)... 22, 2014  ( www.competitivehealth.com ) — Competitive Health ... bill review and advocacy service, has signed an agreement ... Savings discount health services marketplace. 63% of ... than they expected to pay. As part of an ... WellCard Savings is pleased to offer medical bill review ...
(Date:12/22/2014)... Chicago, Illinois (PRWEB) December 22, 2014 ... representing tenants and occupiers of commercial real estate, has ... two new offices in Perth and Brisbane, Western Australia, ... board of directors. , ITRA Global / ACORPP ... and totally independent consultancy company providing property services to ...
(Date:12/19/2014)... 19, 2014 Bioject Medical Technologies ... manufacturer of needle-free injection technology, today announced that ... Therapeutics, Inc. (“ITI”) for ITI to use the ... LAMP™ vaccine platform. , In the agreement, ... license to the Biojector®-2000 that triggers based on ...
Breaking Biology Technology:ALNE Announces Intention To Acquire BioTechPharma 2WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... July 8 Cornerstone Therapeutics Inc. (Nasdaq: ... special meeting of its stockholders on August 27, 2009. ... will be asked to approve a series of amendments ... implement governance arrangements and provide Chiesi Farmaceutici SpA with ...
... SAN DIEGO, July 8 Biomatrica today announced that ... SampleMatrix room temperature storage technology to archive its DNA ... SampleMatrix technology in place of ultra-low-temperature freezers for the ... SMGF will move its collection of previously archived samples ...
... Researchers at Cellular Dynamics ... pluripotent stem cells, which have the ability to generate all ... ordinary human blood samples. This significant breakthrough provides a readily ... samples in storage at blood repositories and healthcare institutions worldwide. ...
Cached Biology Technology:Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments 2Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments 3Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments 4Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments 5Sorenson Molecular Genealogy Foundation to Protect Archived DNA Using Biomatrica's Room Temperature Storage 2Sorenson Molecular Genealogy Foundation to Protect Archived DNA Using Biomatrica's Room Temperature Storage 3Cellular Dynamics International Reprograms Blood Cells into Stem Cells 2
(Date:12/19/2014)... 18, 2014  23andMe, Inc., the leading personal genetics ... pinpoints fine-scale differences in genetic ancestry of individuals from ... Since immigrants first arrived more than four hundred ... has served as a meeting place for peoples from ... the ongoing mixing of peoples with African, European, and ...
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a leader ... PerformTek biometric technology to industry leaders such as Intel, ... clinically validated, biometric wearable products. These products will be ... Las Vegas . ... accurate, flexible and robust – with the clinical data ...
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... their offering. One major trend ... multimodal biometric systems. Multimodal biometric systems utilize more ... and identification purposes. This helps to reduce the ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... has been shown to cause pain by exciting the ... and the hot, spicy ingredient in chili peppers, UCSF ... plants and animals have evolved the same molecular strategy ... specific receptor on sensory nerves. The research provides new ...
... hold promise for reducing the destruction of dopaminergic cells ... lost to the disease, scientists say. , Research ... Neuroscience shows a human neural stem cell transplant essentially ... normally rather than displaying the progressive loss of movement ...
... discovered that mutations in a gene known as SOS1 ... common childhood genetic disorder which occurs in one in ... stature, facial abnormalities, and learning disabilities, as well as ... Led by researchers at Harvard Medical School-Partners Healthcare ...
Cached Biology News:Tarantula venom and chili peppers target same pain sensor 2Transplanted brain cells hold promise for Parkinson's disease 2Transplanted brain cells hold promise for Parkinson's disease 3Study uncovers mutation responsible for Noonan Syndrome 2
Gentamicin sulfate, 5g...
E2F2 protein...
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
Anti-ACTH Immunogen: Porcine ACTH conjugated to BSA. Available Date: 38566...
Biology Products: